SCHEMBL5018907

SCHEMBL5018907

CC(C)c1ccnc2cc(C(F)(F)F)ccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.48
NCF1 P14598 1/20 0.48
GAK O14976 2/20 0.46
PARP1 P09874 1/20 0.45
AAK1 Q2M2I8 3/20 0.43
GRM4 Q14833 1/20 0.42
KDR P35968 3/20 0.41
GSK3A P49840 3/20 0.41
GSK3B P49841 3/20 0.41
CLK4 Q9HAZ1 3/20 0.41
PRKD3 O94806 2/20 0.41
MAP4K4 O95819 2/20 0.41
AURKB Q96GD4 2/20 0.41
PRKD2 Q9BZL6 2/20 0.41
DYRK3 O43781 2/20 0.41
DYRK1A Q13627 2/20 0.41
STK17A Q9UEE5 2/20 0.41
PLK4 O00444 1/20 0.41
CHEK2 O96017 1/20 0.41
FGFR1 P11362 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16999980 0.87 RIPK2 (0.47) ADRB2NCF1GAKAAK1KDR
SCHEMBL29707948 0.80 ADRB2 (0.45) ADRB2NCF1GAKPARP1AAK1
SCHEMBL3524941 0.80 ADRB2 (0.45) ADRB2NCF1GAKPARP1AAK1
SCHEMBL22854 0.80 ADRB2 (0.52) ADRB2NCF1GAKPARP1GRM4
SCHEMBL30174440 0.80 ADRB2 (0.52) ADRB2NCF1GAKPARP1GRM4
SCHEMBL16013596 0.79 ADRB2 (0.44) ADRB2NCF1GAKPARP1AAK1
SCHEMBL16342271 0.78 PARP1 (0.43) ADRB2NCF1GAKPARP1AAK1
SCHEMBL22648432 0.78 FERMT2 (0.45) GAKAAK1GRM4CDK2CDK5
SCHEMBL13409691 0.77 GAK (0.49) ADRB2NCF1GAKPARP1AAK1
SCHEMBL22304444 0.76 LOXL2 (0.36) AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178490-B2 Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof REMPEX PHARMACEUTICALS, INC. (US) 2012-05-15 US disclosed
US-20100152098-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF MPEX PHARMACEUTICALS, INC. (US) 2010-06-17 US disclosed
WO-2010054102-A2 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF MPEX PHARMACEUTICALS, INC. (US) 2010-05-14 WO disclosed
US-20080318957-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF MPEX PHARMACEUTICALS, INC. (US) 2008-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152098-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF ABCB11, ABCB1, SLC47A1 ADRB2 4367/4885NCF1 2465/4885GAK 3335/4885
US-20080318957-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF ABCB11, ABCB1, SLC47A1 ADRB2 4367/4885NCF1 2465/4885GAK 3335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.